Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 4trastuzumab deruxtecan 3fludarabine 3Standard of Care 3Injections 3Cisplatin 3Bevacizumab 3toripalimab 2sacituzumab govitecan 2pembrolizumab 2fludarabine phosphate 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Palliative Care 2Gemcitabine 2Fulvestrant 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1vedolizumab 1tislelizumab 1sintilimab 1ribociclib 1lobaplatin 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1exemestane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm Metastasis × ivosidenib × Clear all
NCT06593548 2024-09-19

Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

Fudan University

Phase 2 Not yet recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡